Roivant Sciences Ltd (ROIV) concluded trading on Thursday at a closing price of $10.76, with 3.78 million shares of worth about $40.64 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -8.89% during that period and on May 15, 2025 the price saw a gain of about 0.84%. Currently the company’s common shares owned by public are about 719.63M shares, out of which, 439.45M shares are available for trading.
Stock saw a price change of -2.45% in past 5 days and over the past one month there was a price change of 6.96%. Year-to-date (YTD), ROIV shares are showing a performance of -9.04% which decreased to -3.76% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.73 but also hit the highest price of $13.06 during that period. The average intraday trading volume for Roivant Sciences Ltd shares is 6.68 million. The stock is currently trading -1.81% below its 20-day simple moving average (SMA20), while that difference is up 1.94% for SMA50 and it goes to -4.41% lower than SMA200.
Roivant Sciences Ltd (NASDAQ: ROIV) currently have 719.63M outstanding shares and institutions hold larger chunk of about 68.82% of that.
The stock has a current market capitalization of $7.68B and its 3Y-monthly beta is at 1.16. It has posted earnings per share of -$0.14 in the same period. It has Quick Ratio of 37.91 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ROIV, volatility over the week remained 3.47% while standing at 2.94% over the month.
Stock’s fiscal year EPS is expected to drop by -109.96% while it is estimated to decrease by -114.71% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on February 15, 2024 offering an Outperform rating for the stock and assigned a target price of $17 to it. Coverage by Piper Sandler stated Roivant Sciences Ltd (ROIV) stock as an Overweight in their note to investors on January 05, 2024, suggesting a price target of $20 for the stock. On December 12, 2023, Deutsche Bank Initiated their recommendations, while on October 17, 2023, Guggenheim Initiated their ratings for the stock with a price target of $17. Stock get a Neutral rating from BofA Securities on June 08, 2023.
